Hainan Tongyong Kangli Pharmaceutical Co., Ltd.
-
Founded in:
2000-05-16 -
Country:
China -
Address:
Room 221-226, Building 1, No. 269, Nanhai Avenue, National High-tech Industrial Development Zone, Haikou City, Hainan Province -
Tax NO.:
914600007212236930 -
Registered Funds:
50 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Dexamethasone sodium phosphate |
Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. Its mechanism of action is: 1. Anti-inflammatory effect: It reduces and prevents the tissue's response to inflammation, thereby reducing the manifestations of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes, at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effect: It includes preventing or inhibiting cell-mediated immune responses, delayed allergic reactions, reducing the number of T lymphocytes, monocytes, and eosinophils, reducing the ability of immunoglobulins to bind to cell surface receptors, and inhibiting the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts and reducing the expansion of primary immune responses. It also reduces the passage of immune complexes through the basement membrane and can reduce the concentration of complement components and immunoglobulins.
More
Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. Its mechanism of action is: 1. Anti-inflammatory effect: It reduces and prevents the tissue's response to inflammation, thereby reducing the manifestations of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes, at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effect: It includes preventing or inhibiting cell-mediated immune responses, delayed allergic reactions, reducing the number of T lymphocytes, monocytes, and eosinophils, reducing the ability of immunoglobulins to bind to cell surface receptors, and inhibiting the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts and reducing the expansion of primary immune responses. It also reduces the passage of immune complexes through the basement membrane and can reduce the concentration of complement components and immunoglobulins. |
55203-24-2 | 25 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Dexamethasone sodium phosphate |
Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. Its mechanism of action is as follows: 1. Anti-inflammatory effect: This product reduces and prevents tissue response to inflammation, thereby reducing the manifestation of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effect: including preventing or inhibiting cell-mediated immune responses, delayed allergic reactions, reducing the number of T lymphocytes, monocytes, and eosinophils, reducing the ability of immunoglobulins to bind to cell surface receptors, and inhibiting the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts and reducing the expansion of primary immune responses. This product also reduces the passage of immune complexes through the basement membrane and can reduce the concentration of complement components and immunoglobulins.
More
Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. Its mechanism of action is as follows: 1. Anti-inflammatory effect: This product reduces and prevents tissue response to inflammation, thereby reducing the manifestation of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effect: including preventing or inhibiting cell-mediated immune responses, delayed allergic reactions, reducing the number of T lymphocytes, monocytes, and eosinophils, reducing the ability of immunoglobulins to bind to cell surface receptors, and inhibiting the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts and reducing the expansion of primary immune responses. This product also reduces the passage of immune complexes through the basement membrane and can reduce the concentration of complement components and immunoglobulins. |
55203-24-2 | 25 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Calcium folinatc |
This product is a formyl derivative of tetrahydrofolate, mainly used for the rescue of high-dose methotrexate and other folic acid antagonists. It can be converted into tetrahydrofolate by tetrahydrofolate reductase, which can limit the damage of methotrexate to normal cells and reverse the reaction of methotrexate to bone marrow and gastrointestinal mucosa, but it has no obvious effect on the neurotoxicity caused by methotrexate.
More
This product is a formyl derivative of tetrahydrofolate, mainly used for the rescue of high-dose methotrexate and other folic acid antagonists. It can be converted into tetrahydrofolate by tetrahydrofolate reductase, which can limit the damage of methotrexate to normal cells and reverse the reaction of methotrexate to bone marrow and gastrointestinal mucosa, but it has no obvious effect on the neurotoxicity caused by methotrexate. |
6035-45-6 | 6 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Potassium magnesium aspartate |
As a precursor of oxaloacetate in the body, aspartic acid plays an important role in the tricarboxylic acid cycle and participates in the ornithine cycle, combining ammonia and carbon dioxide to form urea. It has a strong affinity for cells and can be used as a carrier of potassium and magnesium ions to help them enter cells, increase the concentration of potassium and magnesium in cells, accelerate the tricarboxylic acid cycle of liver cells, and have a certain effect on improving liver function and reducing serum bilirubin concentration. It is metabolized and excreted from the body through the kidneys.
More
As a precursor of oxaloacetate in the body, aspartic acid plays an important role in the tricarboxylic acid cycle and participates in the ornithine cycle, combining ammonia and carbon dioxide to form urea. It has a strong affinity for cells and can be used as a carrier of potassium and magnesium ions to help them enter cells, increase the concentration of potassium and magnesium in cells, accelerate the tricarboxylic acid cycle of liver cells, and have a certain effect on improving liver function and reducing serum bilirubin concentration. It is metabolized and excreted from the body through the kidneys. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| L-ASPARTIC ACID |
As the precursor of oxaloacetate in the body, it plays an important role in the tricarboxylic acid cycle and participates in the ornithine cycle, combining ammonia and carbon dioxide to form urea. It has a strong affinity for cells and can be used as a carrier of potassium and magnesium ions to help them enter cells, increase the concentration of potassium and magnesium in cells, accelerate the tricarboxylic acid cycle of liver cells, and have a certain effect on improving liver function and reducing serum bilirubin concentration. It is metabolized and excreted from the body through the kidneys.
More
As the precursor of oxaloacetate in the body, it plays an important role in the tricarboxylic acid cycle and participates in the ornithine cycle, combining ammonia and carbon dioxide to form urea. It has a strong affinity for cells and can be used as a carrier of potassium and magnesium ions to help them enter cells, increase the concentration of potassium and magnesium in cells, accelerate the tricarboxylic acid cycle of liver cells, and have a certain effect on improving liver function and reducing serum bilirubin concentration. It is metabolized and excreted from the body through the kidneys. |
79-91mg | 6899-03-2 | 18 |
| Potassium |
As a carrier of potassium ions, it helps them enter cells, increases the concentration of potassium in cells, accelerates the tricarboxylic acid cycle of liver cells, and has a certain effect on improving liver function. It is metabolized and excreted from the body through the kidneys.
More
As a carrier of potassium ions, it helps them enter cells, increases the concentration of potassium in cells, accelerates the tricarboxylic acid cycle of liver cells, and has a certain effect on improving liver function. It is metabolized and excreted from the body through the kidneys. |
10.6-12.2mg | 0 | |
| Magnesium |
As a carrier of magnesium ions, it helps them enter cells, increases the concentration of magnesium in cells, accelerates the tricarboxylic acid cycle of liver cells, and has a certain effect on improving liver function. It is metabolized and excreted from the body through the kidneys.
More
As a carrier of magnesium ions, it helps them enter cells, increases the concentration of magnesium in cells, accelerates the tricarboxylic acid cycle of liver cells, and has a certain effect on improving liver function. It is metabolized and excreted from the body through the kidneys. |
3.9-4.5mg | 0 |